Gyre Therapeutics, Inc.

GYRE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.

6.08 0.32 −5.00%
Market cap
$678.6M
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
4/9
Altman Z
16.83
Beneish M
−2.02
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
52.43 26.67 33.51 25.18 46.85 79.35 76.87 120.18 37.78 36.53
Receivables
31.31 24.78 16.45 17.14 1.82 3.31 15.00 — — 0.03
Inventory
10.17 6.34 4.28 6.12 — — — — — —
Other current assets
1.49 1.44 1.05 0.84 2.81 6.84 4.20 3.81 1.33 0.96
Total current assets
102.37 64.79 57.22 49.65 51.48 89.51 96.07 123.99 39.11 37.52
Property, Plant, Equpment (Net)
23.60 23.88 23.29 17.71 0.97 0.43 0.30 0.39 0.28 0.44
Long-Term Investments
23.52 24.57 23.43 7.39 — 2.54 — — — 0.13
Long-term receivables
— — 4.72 — — — — — — —
Goodwill and Intangible Assets (Total)
6.15 1.71 1.70 1.86 — — — — — —
Long Term Assets (Tax, Deferred)
6.87 5.62 4.70 4.08 — — — — — —
Long-term assets (Other)
2.49 3.03 1.00 3.39 0.47 0.53 0.26 0.54 0.13 0.13
Total non-current assets
63.76 60.62 59.32 35.10 4.19 5.34 2.49 0.93 0.40 0.57
Total Assets
166.13 125.41 116.54 84.75 55.66 94.85 98.55 124.92 39.51 38.09
Accounts Payable
0.12 0.11 0.36 0.12 6.42 5.93 4.28 1.25 0.75 0.84
Accrued Expenses
14.35 10.62 11.94 9.26 1.47 2.48 2.11 1.50 1.37 0.60
Current Part of Debt
— — — — — — — — 5.09 19.40
Current Part of Taxes to Pay
2.94 2.83 5.05 2.10 — — — — — —
Current Revenue (Deferred)
— — 0.04 0.15 0.23 1.98 15.00 0.02 0.22 0.32
Other current liabilities
0.01 5.02 0.04 5.00 5.77 11.20 24.14 3.55 2.91 1.73
Total current liabilities
18.29 19.52 20.05 12.24 14.17 17.80 28.90 4.80 8.74 21.97
Non-current Revenue (Deferred)
— — — — — — — 0.17 — 0.05
Non-current Liabilities (Other)
5.26 6.60 17.82 0.17 — — — 0.17 — 0.01
Total non-current liabilities
5.56 7.49 18.02 0.29 0.41 0.98 1.32 0.17 — 0.05
Total liabilities
23.85 27.00 38.07 12.54 14.57 18.78 30.22 4.98 8.74 22.02
Additional Paid In Capital
172.05 136.19 68.18 32.80 443.75 390.80 326.81 323.28 204.26 164.05
Preferred Stock (Total)
— — 64.53 33.31 — — — — — —
Common Stock (Net)
0.09 0.09 0.08 0.06 0.03 0.02 0.01 0.01 0.01 0.00
Retained Earnings
(68.43) (73.45) (85.54) 7.40 (402.69) (314.76) (258.52) (203.34) (173.49) (147.98)
Shareholders Equity (Other)
3.10 3.10 3.10 2.66 — — — — — —
Common Equity (Total)
142.28 98.40 13.95 72.22 41.09 76.07 68.34 119.95 30.77 16.07
Shareholders Equity (Total)
142.28 98.40 78.47 72.22 41.09 76.07 68.34 119.95 30.77 16.07
Shareholders Equity and Liabilities (Total)
166.13 125.41 116.54 84.75 55.66 94.85 98.55 124.92 39.51 38.09
Shares (Common)
91.31 86.31 76.60 63.59 2.10 1.47 0.80 0.80 0.41 0.05
Shares (Preferred)
— — 0.01 0.00 — — — — 0.00 —
Shareholders Equity (Tangible)
136.13 96.70 76.78 70.36 41.09 76.07 68.34 119.95 30.77 16.07
Net Debt
(52.42) (26.67) (33.51) (25.17) (46.85) (79.35) (76.86) (120.18) (32.69) (17.13)
Total Debt
— — — 0.04 1.98 0.66 0.48 — 5.09 19.40

Fold the line items

In millions of $ except per-share values · columns are period end dates